Drug intelligence / Profile preview

TOL 3022

Development stage: Unknown
Lead developer: Tolmar
Modality: Small Molecules
Administration: Subcutaneous

Overview

TOL 3022 is an investigational drug candidate currently in Phase 1 clinical development by Tolmar for the treatment of oncology indications. While specific details regarding its molecular target and active pharmaceutical ingredient are not publicly disclosed, the drug is part of Tolmar's specialized pipeline of long-acting injectables (LAIs). TOL 3022 likely utilizes Tolmar's proprietary ATRIGEL delivery technology, which involves a biodegradable polymer-based system designed to provide controlled, sustained release of a therapeutic agent over an extended period following a single subcutaneous or intramuscular injection. The program is categorized under general oncology in the company's research and development portfolio.

Beyond the preview

Go deeper on TOL 3022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOL 3022.

Explore the full profile